Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Trastuzumab Rezetecan in Advanced Solid Tumors Refractory to Standard Therapies — Stella

Home/Urachal Cancer/Trastuzumab Rezetecan in Advanced Solid Tumors Refractory to Standard Therapies

View on ClinicalTrials.gov

Recruiting

Back to Urachal Cancer trials

Trastuzumab Rezetecan in Advanced Solid Tumors Refractory to Standard Therapies

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(1 site)

China

Fudan University Shanghai Cancer Center, Shanghai, Shanghai Municipality

Key details

Phase

Safety & dosing

Sponsor

Sheng Zhang

Enrollment target

~90 participants

Started

December 2025

Primary completion

September 2027

Age range

18 Years and older

Last updated December 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.